Last reviewed · How we verify
Insulin glargine combined with metformin
This combination uses insulin glargine to provide basal insulin replacement while metformin reduces hepatic glucose production and improves insulin sensitivity.
This combination uses insulin glargine to provide basal insulin replacement while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin glargine combined with metformin |
|---|---|
| Also known as | Lantus®, Sanofi |
| Sponsor | Sun Yat-sen University |
| Drug class | Insulin + biguanide combination |
| Target | Insulin receptor (insulin glargine); AMP-activated protein kinase and mitochondrial complex I (metformin) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine is a long-acting basal insulin that mimics endogenous insulin secretion to lower blood glucose. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they address both insulin deficiency and insulin resistance in type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbance (metformin component)
- Injection site reactions
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects (PHASE2)
- HbA1c Variability in Type II Diabetes (NA)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: